Inhibition of MHC II gene transcription by nitric oxide and antioxidants

Current Pharmaceutical Design

Volumn 10, Issue 8, 2004, Pages 893-898

  Harari, Olivier ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 AMINOSTEROID; ACETYLCYSTEINE; ANTIOXIDANT; CATALASE; CELASTROL; GAMMA INTERFERON; HYDROGEN PEROXIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE MACROGOL; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIOXIDANT ACTIVITY; CELL TYPE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIOXIDANTS; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; NITRIC OXIDE; TRANSCRIPTION, GENETIC;

EID: 1642407149     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452893     Document Type: Review

References (64)

1. Benacerraf B. Role of MHC gene products in immune regulation. Science 1981; 212(4500): 1229-38.
2. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994; 12: 259-93.
3. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001; 19: 331-73.
4. Davies DA, Manstone AJ, Viza DC, Colombani J, Dausset J. Human transplantation antigens: The HL-A (Hu-1) system and its homology with the mouse H-2 system. Transplantation 1968; 6(4): 571-86.
5. Kisielow P, Teh HS, Bluthmann H, von Boehmer H. Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 1988; 335(6192): 730-3.
6. Zepp F, Staerz UD. Thymic selection process induced by hybrid antibodies. Nature 1988; 336(6198): 473-5.
7. McDevitt HO. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr Opin Immunol 1998; 10(6): 677-81.
8. Pober JS, Collins T, Gimbrone MA Jr, Cotran RS, Gitlin JD, Fiers W, et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature 1983; 305(5936): 726-9.
9. Soberman RJ. The expanding network of redox signaling: New observations, complexities, and perspectives. J Clin Invest 2003; 111(5): 571-4.
10. Carrasco-Marin E, Paz-Miguel JE, Lopez-Mato P, Alvarez-Dominguez C, Leyva-Cobian F. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells. Immunology 1998; 95(3): 314-21.
11. Van Heerebeek L, Meischl C, Stooker W, Meijer CJ, Niessen HW, Roos D. NADPH oxidase(s): New source(s) of reactive oxygen species in the vascular system? J Clin Pathol 2002; 55(8): 561-8.
12. Forman HJ, Torres M. Reactive oxygen species and cell signaling: Respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002; 166(12 Pt 2): S4-8.
13. Nathan C. Inducible nitric oxide synthase: What difference does it make? J Clin Invest 1997; 100(10): 2417-23.
14. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res 1983; 52(3): 352-7.
15. Pfeilschifter J, Eberhardt W, Beck KF. Regulation of gene expression by nitric oxide. Pflugers Arch 2001; 442(4): 479-86.
16. Kielar ML, Sicher SC, Penfield JG, Jeyarajah DR, Lu CY. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes - class II MHC, Ii and H-2M. Class II TransActivator. Inflammation 2000; 24(5): 431-45.
17. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96(1): 60-8.
18. Grimm M, Spiecker M, De Caterina R, Shin WS, Liao JK. Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem 2002; 277(29): 26460-7.
19. Heuschling P. Nitric oxide modulates gamma-interferon-induced MHC class II antigen expression on rat astrocytes. J Neuroimmunol 1995; 57(1-2): 63-9.
20. Colasanti M, Mollace V, Cundari E, Massoud R, Nistico G, Lauro GM. The generation of nitric oxide participates in gamma IFN-induced MHC class II antigen expression by cultured astrocytoma cells. Int J Immunopharmacol 1993; 15(6): 763-71.
21. Schuberth HJ, Hendricks A, Leibold W. There is no regulatory role for induced nitric oxide in the regulation of the in vitro proliferative response of bovine mononuclear cells to mitogens, alloantigens or superantigens. Immunobiology 1998; 198(4): 439-50.
22. Xu LY, Yang JS, Link H, Xiao BG. SIN-1, a nitric oxide donor, ameliorates experimental allergic encephalomyelitis in Lewis rats in the incipient phase: The importance of the time window. J Immunol 2001; 166(9): 5810-6.
23. Salahudeen A, Wang C, McDaniel O, Lagoo-Denadyalan S, Bigler S, Barber H. Antioxidant lazaroid U-74006F improves renal function and reduces the expression of cytokines, inducible nitric oxide synthase, and MHC antigens in a syngeneic renal transplant model. Partial support for the response-to-injury hypothesis. Transplantation 1996; 62(11): 1628-33.
24. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(7): 1341-57.
25. Ting JP, Trowsdale J, Genetic control of MHC class II expression. Cell 2002; 109 Suppl: S21-33.
26. Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Landmann S, et al. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 2000; 178: 148-65.
27. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997; 16(5): 1045-55.
28. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998; 20(3): 273-7.
29. Steimle V, Mach B. Complementation cloning of mammalian transcriptional regulators: The example of MHC class II gene regulators. Curr Opin Genet Dev 1995; 5(5): 646-51.
30. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75(1): 135-46.
31. Harton JA, Ting JP. Class II transactivator: Mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000; 20(17): 6185-94.
32. Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996; 4(2): 167-78.
33. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM. MHC class II enhanceosome: How is the class II transactivator recruited to DNA-bound activators? Int Immunol 2003; 15(4): 467-75.
34. Jabrane-Ferrat N, Fontes JD, Boss JM, Peterlin BM. Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions. Mol Cell Biol 1996; 16(9): 4683-90.
35. Peretti M, Villard J, Barras E, Zufferey M, Reith W. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol Cell Biol 2001; 21(17): 5699-709.
36. Ivashkiv LB, Liou HC, Kara CJ, Lamph WW, Verma IM, Glimcher LH. mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol Cell Biol 1990; 10(4): 1609-21.
37. Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, et al. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science 1990; 247(4950): 1581-4.
38. Andersson G, Peterlin BM. NF-X2 that binds to the DRA X2-box is activator protein 1. Expression cloning of c-Jun. J Immunol 1990; 145(10): 3456-62.
39. Wright KL, Vilen BJ, Itoh-Lindstrom Y, Moore TL, Li G, Criscitiello M, et al. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. EMBO J 1994; 13(17): 4042-53.
40. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16(10): 2851-60.
41. Landmann S, Muhlethaler-Mottet A, Bernasconi L, Suter T, Waldburger JM, Masternak K, et al. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 2001; 194(4): 379-91.
42. Ghosh N, Piskurich JF, Wright G, Hassani K, Ting JP, Wright KL. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J Biol Chem 1999; 274(45): 32342-50.
43. Waldburger JM, Suter T, Fontana A, Acha-Orbea H, Reith W. Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med 2001; 194(4): 393-406.
44. Li G, Harton JA, Zhu X, Ting JP. Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: Mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines. Mol Cell Biol 2001; 21(14): 4626-35.
45. Shuai K, Ziemiecki A, Wilks AF, Harpur AG, Sadowski HB, Gilman MZ, et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 1993; 366(6455): 580-3.
46. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998; 95(18): 10626-31.
47. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387(6636): 924-9.
48. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387(6636): 921-4.
49. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387(6636): 917-21.
50. David M, Chen HE, Goelz S, Larner AC, Neel BG. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 1995; 15(12): 7050-8.
51. Chang Y, Ceacareanu B, Dixit M, Sreejayan N, Hassid A. Nitric oxide-induced motility in aortic smooth muscle cells: Role of protein tyrosine phosphatase SHP-2 and GTP-binding protein Rho. Circ Res 2002; 91(5): 390-7.
52. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 2002; 23(2): 96-101.
53. Song JH, So EY, Lee CE. Increased serine phosphorylation and activation of STAT1 by oncogenic Ras transfection. Mol Cells 2002; 13(2): 322-6.
54. Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol 1998; 275(6 Pt 1): C1640-52.
55. Cunnick JM, Dorsey JF, Mei L, Wu J. Reversible regulation of SHP-1 tyrosine phosphatase activity by oxidation. Biochem Mol Biol Int 1998; 45(5): 887-94.
56. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20(10): 2175-83.
57. Abate C, Patel L, Rauscher FJ 3rd, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990; 249(4973): 1157-61.
58. Tabuchi A, Sano K, Oh E, Tsuchiya T, Tsuda M. Modulation of AP-1 activity by nitric oxide (NO) in vitro: NO-mediated modulation of AP-1. FEBS Lett 1994; 351(1): 123-7.
59. Duh JL, Zhu H, Shertzer HG, Nebert DW, Puga A. The Y-box motif mediates redox-dependent transcriptional activation in mouse cells. J Biol Chem 1995; 270(51): 30499-507.
60. Nenoi M, Ichimura S, Mita K, Yukawa O, Cartwright IL. Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors, and a WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer Res 2001; 61(15): 5885-94.
61. Luo D, Rando TA. The regulation of catalase gene expression in mouse muscle cells is dependent on the CCAAT-binding factor NF-Y. Biochem Biophys Res Commun 2003; 303(2): 609-18.
62. Alfano M, Poli G. Cytokine and chemokine based control of HIV infection and replication. Curr Pharm Design 2001; 7(11): 993-1013.
63. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: A review and therapeutical perspectives. Curr Pharm Design 2001; 7(2): 89-111.
64. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Design 2002; 8(3): 155-66.